Adult Immunization Schedule for Providers

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older: United States, 2018. released February 2018

Kim DK, Riley LE, Hunter P. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2018. MMWR Morb Mortal Wkly Rep 2018;67:158–160. DOI: http://dx.doi.org/10.15585/mmwr.mm6705e3.

Key Updates Include:

Tdap or Td vaccines 

  • Td/Tdap” has been replaced by “Tdap or Td” on Figures 1 and 2 and the text in the indication bar has been revised to “1 dose Tdap, then Td booster every 10 years."

MMR vaccine

  • Administer 1 dose of MMR to adults who previously received ≤2 doses of mumps-containing vaccine and are identified by a public health authority to be at increased risk during a mumps outbreak.
  • The text in the indication bar for Figure 1 for MMR has been changed to “1 or 2 doses depending on indication (if born in 1957 or later)."

Zoster vaccines

  • Administer 2 doses of recombinant zoster vaccine (RZV) (Shingrix) 2–6 months apart to adults aged 50 years or older regardless of past episode of herpes zoster or receipt of zoster vaccine live (ZVL) (Zostavax).
  • Administer 2 doses of RZV 2–6 months apart to adults who previously received ZVL at least 2 months after ZVL.
  • For adults aged 60 years or older, administer either RZV or ZVL (RZV is preferred).
  • “ZVL” has replaced the term “HZV” (herpes zoster vaccine) that was used in past adult immunization schedules to refer to the live zoster vaccine. A row for RZV was added above the row for ZVL and a dashed line was used to separate RZV and ZVL rows to denote that the 2 zoster vaccines are recommended for the same purpose.

HPV vaccine

  • In Figure 1, the text in the indication bars for HPV vaccine for females and males has been revised to “2 or 3 doses depending on age at series initiation.”

MenACWY vaccine

  • In figures 1 and 2, the text in the indication bar for MenACWY (serogroups A, C, W, and Y meningococcal vaccine) has been revised to “1 or 2 doses depending on indication, then booster every 5 years if risk remains.”
  • MPSV4 (4-valent meningococcal polysaccharide vaccine) is no longer available and has been removed from the adult immunization schedule.

 
 
 
 
 
Updated 5/14/18
 

This website is supported by an independent educational grant from Merck and an educational grant from Sanofi Pasteur U.S. 
ACOG does not allow companies to influence its programs, publications, or advocacy positions.